QIAGEN expands business in Middle East with new regional headquarters and major projects
January 03 2024 - 2:00AM
QIAGEN (NYSE: QGEN; Frankfurt Prime Standard: QIA) today announced
a significant expansion of its business in the Middle East region,
which includes three major developments:
-
In early 2024, QIAGEN will open its regional headquarters in
Riyadh, Saudi Arabia, in order to further strengthen its commercial
footprint in the region.
-
It has signed a memorandum of understanding (MoU) with the Ministry
of Health of Saudi Arabia, addressing various public health and
infection control initiatives.
-
QIAGEN has been awarded a tender through its Commercial Partner
Taiba Medserv LLC from the Ministry of Health of the Sultanate of
Oman to provide the country with QuantiFERON-TB Gold Plus tests for
its nationwide tuberculosis (TB) screening program.
“At QIAGEN, we believe that improving healthcare
outcomes starts with a strong foundation of collaboration and
innovation, and we are excited to play a crucial role in advancing
health and well-being throughout the Middle East. We are proud to
contribute to the global efforts to end TB and other serious health
threats. Our new regional headquarters in Riyadh will enable us to
better serve our customers and foster strong partnerships with
local stakeholders,” said Simona Grandits, Senior Director, Head of
Sales and Marketing EEMEA at QIAGEN.
Saudi Arabia: New regional headquarters and
Memorandum of Understanding with Ministry of Health
To accommodate its growing regional presence and
customer needs, QIAGEN will inaugurate its new regional
headquarters in Riyadh, Saudi Arabia, at the beginning of 2024.
This office will further strengthen the company’s commitment to the
Middle East and improve its ability to serve clients in the
area.QIAGEN has recently signed an MoU with the Ministry of Health
of Saudi Arabia that covers various public health and infection
control initiatives and aligns with the Health Sector
Transformation Program of Saudi Arabia’s Vision 2030. The MoU
includes:
-
Establishing a localized data center by QIAGEN Digital Insights
(QDI) to support advanced bioinformatics within the country,
ensuring data protection, and robust service while complying with
national legislation. The data center will enable in-country
molecular data analysis without information leaving the country and
provide localized access to QIAGEN Clinical Insight (QCI)
Interpret. QCI Interpret assists in interpreting and reporting
genomic variants from next-generation sequencing data, facilitating
precision medicine. With expertise in installing essential
infrastructure, including bioinformatics servers, QDI currently
operates seven data centers worldwide.
-
Assisting the Ministry in eliminating meningitis per the World
Health Organization (WHO) program using QIAGEN’s syndromic testing
platform QIAstat-Dx.
-
Supporting the implementation of a prevention screening program for
cervical cancer under the WHO elimination initiative by 2030,
supplying the country with HPV tests.
-
Developing a national latent TB screening program using
QuantiFERON-TB Gold Plus.
Oman: Supporting nationwide tuberculosis
screening program
QIAGEN, through its Commercial Partner Taiba
Medserv LLC, will provide hundreds of thousands of QuantiFERON-TB
Gold Plus assays to Oman’s new program, which aims to test for
latent tuberculosis (TB) in expatriates applying for residency in
the Gulf state starting in early 2024. As a country with a
low incidence of TB and a large workforce from high-incidence
countries, Oman is expanding its TB testing policy for residency
applicants by adding systematic screening for latent TB infection
using QIAGEN’s simple standard-setting QuantiFERON-TB Gold Plus
blood test. The Ministry of Health plans to test up to 800,000
people over two years and offer direct medical treatment to those
found carrying TB bacteria without symptoms.
Screening for latent TB infections is vital in
the effort to end TB, a disease that claims over a million lives
each year. One in four people across the globe are thought to have
latent TB infections, with 5-10% of them expected at some point to
develop active TB.
QIAGEN’s QuantiFERON-TB Gold Plus assay
accurately detects TB infection by identifying interferon-gamma
released by T-cells in response to TB-specific antigens. This
one-visit test outperforms the century-old, two-visit TB skin test
(TST), particularly for patients from high-TB-burden countries who
have received BCG vaccination. The CDC and WHO endorse the use of
QuantiFERON-TB Gold Plus in all settings to combat the global TB
epidemic.
About QIAGEN
QIAGEN N.V., a Netherlands-based holding
company, is the leading global provider of Sample to Insight
solutions that enable customers to gain valuable molecular insights
from samples containing the building blocks of life. Our sample
technologies isolate and process DNA, RNA and proteins from blood,
tissue and other materials. Assay technologies make these
biomolecules visible and ready for analysis. Bioinformatics
software and knowledge bases interpret data to report relevant,
actionable insights. Automation solutions tie these together in
seamless and cost-effective workflows. QIAGEN provides solutions to
more than 500,000 customers around the world in Molecular
Diagnostics (human healthcare) and Life Sciences (academia, pharma
R&D and industrial applications, primarily forensics). As of
September 30, 2023, QIAGEN employed more than 6,000 people in over
35 locations worldwide. Further information can be found at
http://www.qiagen.com.
Forward-Looking Statement
Certain statements contained in this press
release may be considered forward-looking statements within the
meaning of Section 27A of the U.S. Securities Act of 1933, as
amended, and Section 21E of the U.S. Securities Exchange Act of
1934, as amended. To the extent that any of the statements
contained herein relating to QIAGEN's products, including those
products used in the response to the COVID-19 pandemic, timing for
launch and development, marketing and/or regulatory approvals,
financial and operational outlook, growth and expansion,
collaborations, markets, strategy or operating results, including
without limitation its expected adjusted net sales and adjusted
diluted earnings results, are forward-looking, such statements are
based on current expectations and assumptions that involve a number
of uncertainties and risks. Such uncertainties and risks include,
but are not limited to, risks associated with management of growth
and international operations (including the effects of currency
fluctuations, regulatory processes and dependence on logistics),
variability of operating results and allocations between customer
classes, the commercial development of markets for our products to
customers in academia, pharma, applied testing and molecular
diagnostics; changing relationships with customers, suppliers and
strategic partners; competition; rapid or unexpected changes in
technologies; fluctuations in demand for QIAGEN's products
(including fluctuations due to general economic conditions, the
level and timing of customers' funding, budgets and other factors);
our ability to obtain regulatory approval of our products;
difficulties in successfully adapting QIAGEN's products to
integrated solutions and producing such products; the ability of
QIAGEN to identify and develop new products and to differentiate
and protect our products from competitors' products; market
acceptance of QIAGEN's new products and the integration of acquired
technologies and businesses; actions of governments, global or
regional economic developments, weather or transportation delays,
natural disasters, political or public health crises, including the
breadth and duration of the COVID-19 pandemic and its impact on the
demand for our products and other aspects of our business, or other
force majeure events; as well as the possibility that expected
benefits related to recent or pending acquisitions may not
materialize as expected; and the other factors discussed under the
heading “Risk Factors” contained in Item 3 of our most recent
Annual Report on Form 20-F. For further information, please refer
to the discussions in reports that QIAGEN has filed with, or
furnished to, the U.S. Securities and Exchange Commission.
Source: QIAGEN N.V.Category: Corporate
John Gilardi
QIAGEN N.V.
+49 2103 29 11711
ir@qiagen.com
Phoebe Loh
QIAGEN N.V.
+49 2103 29 11457
ir@qiagen.com
Thomas Theuringer
QIAGEN N.V.
+49 210 329 11826
pr@qiagen.com
Daniela Berheide
QIAGEN N.V.
+49 2103 29 11676
pr@qiagen.com
Qiagen NV (NYSE:QGEN)
Historical Stock Chart
From Apr 2024 to May 2024
Qiagen NV (NYSE:QGEN)
Historical Stock Chart
From May 2023 to May 2024